# BPC-157 TB-500: The Wolverine Two-Peptide Research Blend > BPC-157 TB-500 is the research-community 'Wolverine' blend — two structurally unrelated peptides paired for tissue repair. A cited digest of what each constituent has been studied for and what the combination has not. Two structurally unrelated peptides — a local cytoprotective signal and a cytoskeletal cell-migration signal — read against their own studies, with the combination gauge left honestly at no signal. ## Two peptides, one carved record **BPC-157 TB-500** is the research-community name for a pairing of two distinct synthetic peptides marketed and discussed as a tissue-repair "stack." It is not a single chemical entity: it has no shared molecular weight, no CAS number, and no standardized ratio. The first peptide, BPC-157, is a 15-amino-acid pentadecapeptide derived from a protein found in human gastric juice. The second, TB-500, is a synthetic seven-amino-acid acetylated fragment of the much larger protein Thymosin Beta-4. The two are paired because their proposed mechanisms are complementary. BPC-157 supplies a local cytoprotective and pro-angiogenic signal, up-regulating VEGFR2 with downstream Akt-eNOS activation [2]. TB-500 supplies an intracellular actin-sequestration signal: its LKKTETQ motif binds monomeric G-actin in a 1:1 complex, the structural basis for regulating cell migration [3]. These pathways are largely non-overlapping, and that separation is the entire basis of the "synergy" claim. This site is a carved field record of that literature — each finding logged to its source, each peptide marked to the studies it actually derives from. It does not sell, prescribe, or supply anything. For the regulatory picture, see [Wolverine legal status and FDA 503A category](/legal-status). ## Why BPC-157 and TB-500 are combined The pairing rationale is mechanistic complementarity, not a measured combined result. BPC-157's local angiogenic and cytoprotective signal is proposed to cover the vascular and survival side of repair, while TB-500's cytoskeletal cell-migration signal is proposed to cover the cell-movement side. The two are presented as addressing different stages of tissue repair through different molecular routes. The critical caveat is unmissable: no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint for the two given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine surveyed 36 studies and made no mention of TB-500 or any combination [9]. "Synergy" here is an extrapolation from each peptide's separately characterized mechanism — a hypothesis the published record has not tested. See [why BPC-157 and TB-500 are combined](/research#combination) for the full mechanism discussion. ## What the blend is studied for All efficacy data sit at the level of the individual constituents, in animal models. For BPC-157, the flagship result is tendon repair: in fully transected rat Achilles tendons, BPC-157 improved healing across biomechanical, functional, microscopic, and macroscopic measures, and in cultured tendocytes reversed growth inhibition into stimulation [1]. At the cellular level, BPC-157 enhanced tendon-fibroblast outgrowth, survival, and migration through FAK-paxillin signaling [7], and up-regulated the growth-hormone receptor in tendon fibroblasts [5]. For TB-500, the consolidated mechanism comes from its parent protein. A review of Thymosin Beta-4 describes actin binding, cell mobilization and migration, reduced myofibroblast number (less scarring), anti-inflammatory activity, and angiogenesis [4]. These are single-compound, mostly rodent findings. The blend itself has no controlled efficacy study, and most data attributed to "TB-500" were generated with full-length Thymosin Beta-4, not the seven-amino-acid fragment that is actually sold. ## Reading the record honestly The evidence for both constituents is overwhelmingly preclinical. BPC-157 has only three small human pilot studies; the TB-500 fragment has zero completed controlled human trials, with the human data attributed to it coming from the full-length protein. Recent reviews call BPC-157 investigational and note that rigorous large-scale trials are lacking [11]. Neither constituent is an approved drug. A 2026 narrative review of approved and unapproved musculoskeletal peptides — listing both BPC-157 and Thymosin Beta-4 — concluded that many show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [10]. The honest position is that the combination's human efficacy and safety are unproven, and the [BPC-157 and TB-500 research findings](/research) here are reported as research, not as outcomes a reader should expect. ### What is BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a human gastric-juice protein. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region, residues 17-23, of Thymosin Beta-4. The "Wolverine" blend pairs the two as a research-community tissue-repair stack [3]. ### What Is the Wolverine Peptide Blend? A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed and marketed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or standardized ratio, and is not an approved product anywhere [4]. ### What the Blend Is Studied For Preclinical, mostly rodent research on the two constituents covers tendon, ligament, muscle, and bone repair, wound and soft-tissue healing, cytoprotection, and angiogenesis. These are single-compound, animal-model findings; the blend itself has no controlled efficacy study [1]. ### Why BPC-157 and TB-500 Are Combined The rationale is complementary mechanisms: BPC-157's local cytoprotective and angiogenic signal (VEGFR2-Akt-eNOS) is paired with TB-500's cytoskeletal cell-migration signal, so the two are proposed to cover different stages of tissue repair [2]. Critically, no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint [9]. ### BPC-157 vs TB-500: Two Distinct Compounds They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide (~1419.5 Da) from a gastric-juice protein acting via VEGFR2/eNOS angiogenic and growth-hormone-receptor pathways [2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration [3]. Different sequences, sizes, and mechanisms. ### BPC-157 TB-500 Stack (Wolverine) The community "stack" is the same two-peptide pairing under a different name. There is no validated stack dose, ratio, or schedule, and no combination trial behind the term — the synergy framing is theoretical, drawn from each peptide's separate mechanism [9]. ### BPC 157 TB 500 (Unhyphenated) The unhyphenated spelling BPC 157 TB 500 refers to the identical two-peptide blend; the spacing is a search-surface variant, not a different product [3]. ### Why the Research Community Pairs BPC-157 with TB-500 The research community pairs BPC-157 with TB-500 because their characterized mechanisms are complementary and non-overlapping — a local angiogenic-cytoprotective signal alongside a cytoskeletal migration signal [2]. No controlled combination study has demonstrated that pairing them produces a greater-than-additive effect [9]. --- Two complementary repair signals carved as two mirrored glyph-channels — BPC-157 read against its studies on one side, TB-500 against its own on the other, the join between them left uncarved because no combination trial exists, and the FDA 503A and WADA record set in the margin; no clinic behind the tablet and nothing here dispensed.